All In Biotech

Drug Trial Radar · NCT00258713

A 36-Week Extension to Protocol ISA04-03

A 36-Week Extension to Protocol ISA04-03 to Evaluate the Safety and Efficacy of ISA247 in Patients With Plaque Psoriasis

Last checked: Nov 19, 2026Latest source record: Sep 29, 2008 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 309 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

309

Actual

Start

Sep 2005

Primary completion

Jul 2006

Study completion Jul 2006

Sponsor

Lead sponsor
Aurinia Pharmaceuticals Inc.Industry
Sponsor type
Industry
First posted
Nov 28, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 66 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to determine the safety and efficacy of voclosporin in patients with plaque psoriasis.

Conditions

  • Psoriasis

Interventions

  • voclosporinDrug

    voclosporin 0.2, 0.3, or 0.4 mg/kg BID

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To investigate long-term safety and tolerability of voclosporinTime frame: Sixty weeks of continuous treatment

Locations

29 sites in 1 country. Site status is shown where the registry gives one.

  • Isotechnika Investigational Site

    Calgary, Alberta, Canada

  • Isotechnika Investigational Site

    Edmonton, Alberta, Canada

  • Isotechnika Investigational Site

    Vancouver, British Columbia, Canada

  • Isotechnika Investigational Site

    Vancouver, British Columbia, Canada

  • Isotechnika Investigational Site

    Winnipeg, Manitoba, Canada

  • Isotechnika Investigational Site

    Moncton, New Brunswick, Canada

  • Isotechnika Investigational Site

    St. John's, Newfoundland and Labrador, Canada

  • Isotechnika Investigational Site

    St. John's, Newfoundland and Labrador, Canada

  • Isotechnika Investigational Site

    Halifax, Nova Scotia, Canada

  • Isotechnika Investigational Site

    Barrie, Ontario, Canada

  • Isotechnika Investigational Site

    Hamilton, Ontario, Canada

  • Isotechnika Investigational Site

    London, Ontario, Canada

  • Isotechnika Investigational Site

    London, Ontario, Canada

  • Isotechnika Investigational Site

    Maple, Ontario, Canada

  • Isotechnika Investigational Site

    Markham, Ontario, Canada

  • Isotechnika Investigational Site

    Newmarket, Ontario, Canada

  • Isotechnika Investigational Site

    North Bay, Ontario, Canada

  • Isotechnika Investigational Site

    Oakville, Ontario, Canada

  • Isotechnika Investigational Site

    Oshawa, Ontario, Canada

  • Isotechnika Investigational Site

    Waterloo, Ontario, Canada

  • Isotechnika Investigational Site

    Windsor, Ontario, Canada

  • Isotechnika Investigational Site

    Windsor, Ontario, Canada

  • Isotechnika Investigational Site

    Laval, Quebec, Canada

  • Isotechnika Investigational Site

    Montreal, Quebec, Canada

  • Isotechnika Investigational Site

    Montreal, Quebec, Canada

  • Isotechnika Investigational Site

    Montreal, Quebec, Canada

  • Isotechnika Investigational Site

    Pointe-Claire, Quebec, Canada

  • Isotechnika Investigational Site

    Saint Foy, Quebec, Canada

  • Isotechnika Investigational Site

    Sherbrooke, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.